ガドクアトレインの市場規模、シェア、成長分析：用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

ガドクアトレインの市場規模は2023年に19億米ドルで、予測期間（2025-2032年）のCAGRは5.1%で、2024年の20億米ドルから2032年には29億7,000万米ドルに成長する見通しです。

MRI造影剤市場は、効果的な診断と治療計画のために精密な画像診断が必要とされるがん、神経疾患、心血管疾患などの慢性疾患の罹患率の上昇に後押しされ、大幅な成長が見込まれています。最新の進歩の中には、四量体ガドクアトレインがあり、これは非常に効果的な分子ガドリニウムベースの造影剤（mGBCA）で、高い緩和性と安定性、最小限のタンパク質結合といった優れた物理化学的特性で知られています。この薬剤は、既存のmGBCAの薬物動態プロファイルを反映し、迅速な分布と腎排泄を示します。さらに、高齢者人口の増加と非侵襲的診断技術への傾倒の高まりが、今後数年間の市場成長をさらに促進すると予想され、現代のヘルスケアにおけるMRI造影剤の重要な役割が強調されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ

ガドクアトレイン市場規模：用途別& CAGR（2025-2032）

• 市場概要
• スクリーニング
• 診断

ガドクアトレイン市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 診断センター
• 専門クリニック
• その他

ガドクアトレイン市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Bayer AG（Germany）
• GE Healthcare（United States）
• Guerbet Group（France）
• Bracco Imaging S.p.A.（Italy）
• Lantheus Medical Imaging, Inc.（United States）
• Daiichi Sankyo Company, Limited（Japan）
• Spago Nanomedical AB（Sweden）
• Trivitron Healthcare（India）
• Jodas Expoim Pvt. Ltd.（India）
• CMR Naviscan Corporation（United States）
• Subhra Pharma Pvt. Ltd.（India）
• Macrocyclics, Inc.（United States）
• iMax Diagnostic Imaging Limited（China）
• Beijing Beilu Pharmaceutical Co., Ltd.（China）
• Jiangsu Hengrui Medicine Co., Ltd.（China）
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.（China）
• Yantai Dongcheng Pharmaceutical Group Co., Ltd.（China）
• Sanochemia Pharmazeutika AG（Austria）
• Medtronic plc（Ireland）

結論と提言

Gadoquatrane Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 2.0 billion in 2024 to USD 2.97 billion by 2032, growing at a CAGR of 5.1% during the forecast period (2025-2032).

The MRI contrast media agents market is poised for substantial growth, fueled by the rising incidence of chronic diseases including cancer, neurological disorders, and cardiovascular issues that necessitate precise imaging for effective diagnosis and treatment planning. Among the latest advancements is tetrameric gadoquatrane, a highly effective molecular gadolinium-based contrast agent (mGBCA) known for its superior physicochemical properties, such as high relaxivity and stability, along with minimal protein binding. This agent mirrors the pharmacokinetic profiles of existing mGBCAs, demonstrating rapid distribution and kidney excretion. In addition, the expanding elderly population and the increasing inclination towards non-invasive diagnostic techniques are anticipated to further catalyze market growth over the coming years, underscoring the critical role of MRI contrast agents in contemporary healthcare.

Top-down and bottom-up approaches were used to estimate and validate the size of the Gadoquatrane market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Gadoquatrane Market Segments Analysis

Global Gadoquatrane Market is segmented by Application, End User and region. Based on Application, the market is segmented into Screening and Diagnosis. Based on End User, the market is segmented into Hospital, Diagnostic Centres, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Gadoquatrane Market

The Gadoquatrane market is being driven by the escalating demand for MRI contrast media agents, fueled by several key factors. Notably, the rising prevalence of chronic illnesses, an aging population, and the preference for non-invasive diagnostic methods are significantly contributing to this trend. Additionally, advancements in technology and increased healthcare expenditures are further enhancing market growth. Research has shown the effectiveness of gadolinium-based contrast agents (GBCAs) in contrast-enhanced magnetic resonance imaging (CE-MRI), with over 620 million treatments administered globally and around 30 million CE-MRI procedures conducted annually. GBCAs, particularly those featuring paramagnetic gadolinium, optimize MRI signal enhancement, making Gadoquatrane an exceptional candidate for clinical development and increasing its demand in the market.

Restraints in the Gadoquatrane Market

Several factors contribute to the constraints on demand and subsequent price reduction for MRI contrast media agents in the Gadoquatrane market. Notably, the high costs associated with these agents lead both patients and healthcare providers to consider alternative diagnostic methods, especially in light of the increasing healthcare expenditure. Additionally, advancements in non-contrast MRI techniques are enhancing their accuracy and efficacy, thereby diminishing the reliance on contrast agents. Safety concerns, including rare adverse effects such as allergic reactions and nephrogenic systemic fibrosis (NSF), further discourage use. Furthermore, the healthcare industry's shift towards value-based care promotes high-quality yet cost-effective solutions, encouraging a preference for other imaging modalities like ultrasonography or CT scans, which can further limit the demand for MRI contrast agents.

Market Trends of the Gadoquatrane Market

The Gadoquatrane market is witnessing a significant shift towards safer imaging alternatives due to rising concerns over the side effects associated with gadolinium-based contrast agents, particularly in patients with renal impairments. As healthcare professionals and patients demand improved safety profiles, the focus is increasingly turning to gadolinium-free contrast agents, including innovative iron oxide nanoparticles and manganese-based compounds. This trend not only reflects a growing awareness of patient safety but also opens new avenues for research and development within the pharmaceutical industry. Consequently, the Gadoquatrane market is poised for growth as it aligns with these evolving patient care standards and technological advancements.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Gadoquatrane Market Size by Application & CAGR (2025-2032)

• Market Overview
• Screening
• Diagnosis

Global Gadoquatrane Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital
• Diagnostic Centres
• Specialty Clinics
• Others

Global Gadoquatrane Market Size & CAGR (2025-2032)

• North America (Application, End User)
  • US
  • Canada
• Europe (Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Medical Imaging, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spago Nanomedical AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trivitron Healthcare (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jodas Expoim Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CMR Naviscan Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Subhra Pharma Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macrocyclics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• iMax Diagnostic Imaging Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing Beilu Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Medicine Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanochemia Pharmazeutika AG (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations